Literature DB >> 23961023

Update on advanced imaging options for thyroid-associated orbitopathy.

Michael P Rabinowitz1, Jacqueline R Carrasco.   

Abstract

Thyroid-associated orbitopathy (TAO) is a diverse spectrum of signs and symptoms that appears to have immunologic and pathologic causative factors as diverse as its clinical presentations. Lymphocytes, hormones, and cytokines affect orbital fibroblasts and other similar cells, which exert their effects on orbital tissues, including the extraocular muscles, orbital fat, and optic nerve. This complicated inflammatory cascade and the myriad of clinical findings that result contributes to the active phase of TAO. The distinction between the active and inactive phases of TAO is an important one, as the proper treatment will depend on the disease phase and degree thereof. Several clinical grading scales and scores have been established to help qualify and quantify the disease severity. Aiding clinical exam and acumen, proper and reproducible imaging of the orbit and ocular adnexa is incredibly important to the management of TAO. Orbital ultrasound, computed tomography, magnetic resonance imaging, and scintigraphy each have unique abilities, including quantifying orbital changes, assessing disease activity, correlating orbital findings with clinical changes, guiding appropriate treatment, and monitoring therapeutic responses. Further, study ease, accessibility, cost, sensitivity, specificity, reproducibility, and risks are all important considerations in picking the right test with which to diagnose and follow TAO. This analysis will provide a review of orbital imaging for TAO, including the mechanism of each imaging technique as well as their rationales, advantages, disadvantages, and utilities.

Entities:  

Keywords:  Computed tomography; Graves orbitopathy; Magnetic resonance imaging; Orbital ultrasound; Scintigraphy; Thyroid-associated orbitopathy

Year:  2012        PMID: 23961023      PMCID: PMC3729571          DOI: 10.1016/j.sjopt.2012.07.006

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  88 in total

Review 1.  Octreoscan in thyroid-associated ophthalmopathy.

Authors:  Gerasimos E Krassas
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

2.  Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression.

Authors:  Rui Han; Shanli Tsui; Terry J Smith
Journal:  J Biol Chem       Date:  2002-02-14       Impact factor: 5.157

Review 3.  Neuroradiological diagnosis in thyroid-associated orbitopathy.

Authors:  W Müller-Forell; S Pitz; W Mann; G J Kahaly
Journal:  Exp Clin Endocrinol Diabetes       Date:  1999       Impact factor: 2.949

4.  Extraocular muscle size comparison using standardized A-scan echography and computerized tomography scan measurements.

Authors:  J E Holt; P S O'Connor; J P Douglas; B Byrne
Journal:  Ophthalmology       Date:  1985-10       Impact factor: 12.079

5.  Modification of the classification of the eye changes of Graves' disease.

Authors:  S C Werner
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

6.  Colour Doppler imaging of the orbital vasculature in Graves' disease with computed tomographic correlation.

Authors:  M N Alp; A Ozgen; I Can; P Cakar; I Gunalp
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

7.  Color Doppler imaging of the superior ophthalmic vein in patients with Graves' orbitopathy before and after treatment of congestive disease.

Authors:  Mário L R Monteiro; Rodrigo B S Moritz; Hélio Angotti Neto; Joseph E Benabou
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  Can autoimmunity against calsequestrin explain the eye and eyelid muscle inflammation of thyroid eye disease?

Authors:  Bamini Gopinath; Leon Wescombe; Bao Nguyen; Jack R Wall
Journal:  Orbit       Date:  2009

9.  A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy.

Authors:  M F Prummel; M S Suttorp-Schulten; W M Wiersinga; A M Verbeek; M P Mourits; L Koornneef
Journal:  Ophthalmology       Date:  1993-04       Impact factor: 12.079

10.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

View more
  5 in total

1.  Update in oculoplastic imaging.

Authors:  Imtiaz A Chaudhry
Journal:  Saudi J Ophthalmol       Date:  2012-11-10

2.  Performance of apparent diffusion coefficient of medial and lateral rectus muscles in Graves' orbitopathy.

Authors:  Ahmed Ak Abdel Razek; Mohamed El-Hadidy; Mohamed E Moawad; Nader El-Metwaly; Amr A El-Said
Journal:  Neuroradiol J       Date:  2017-04-05

3.  Fractional anisotropy and diffusivity changes in thyroid-associated orbitopathy.

Authors:  Ji Sung Han; Hyung Suk Seo; Young Hen Lee; Hwa Lee; Sang-Il Suh; Eun-Kee Jeong; Nabraj Sapkota; Ki Joon Kim
Journal:  Neuroradiology       Date:  2016-11-14       Impact factor: 2.804

4.  99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy.

Authors:  B Sun; Z Zhang; C Dong; Y Zhang; C Yan; S Li
Journal:  Eye (Lond)       Date:  2017-04-07       Impact factor: 3.775

5.  Extraocular muscle sampled volume in Graves' orbitopathy using 3-T fast spin-echo MRI with iterative decomposition of water and fat sequences.

Authors:  Ludovico M Garau; Daniele Guerrieri; Flaminia De Cristofaro; Alice Bruscolini; Giuseppe Panzironi
Journal:  Acta Radiol Open       Date:  2018-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.